Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (37)
  • Open Access

    ARTICLE

    A prognosis model for predicting immunotherapy response of esophageal cancer based on oxidative stress-related signatures

    JING GUO1, CHANGYONG TONG1, JIANGUANG SHI1, XINJIAN LI1, XUEQIN CHEN2,*

    Oncology Research, Vol.32, No.1, pp. 199-212, 2024, DOI:10.32604/or.2023.030969

    Abstract Oxidative stress (OS) is intimately associated with tumorigenesis and has been considered a potential therapeutic strategy. However, the OS-associated therapeutic target for esophageal squamous cell carcinoma (ESCC) remains unconfirmed. In our study, gene expression data of ESCC and clinical information from public databases were downloaded. Through LASSO-Cox regression analysis, a risk score (RS) signature map of prognosis was constructed and performed external verification with the GSE53625 cohort. The ESTIMATE, xCell, CIBERSORT, TIMER, and ImmuCellAI algorithms were employed to analyze infiltrating immune cells and generate an immune microenvironment (IM). Afterward, functional enrichment analysis clarified the underlying… More >

  • Open Access

    REVIEW

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

    QIUQIANG CHEN1,*, XUEJUN GUO2, WENXUE MA3,*

    Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383

    Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy… More > Graphic Abstract

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

  • Open Access

    ARTICLE

    Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data

    XUEFENG WANG1,#, SICONG JIANG2,#, XINHONG ZHOU3, XIAOFENG WANG4, LAN LI5, JIANJUN TANG1,*

    Oncology Research, Vol.31, No.5, pp. 697-714, 2023, DOI:10.32604/or.2023.029458

    Abstract Background: Pancreatic cancer is associated with high mortality and is one of the most aggressive of malignancies, but studies have not fully evaluated its molecular subtypes, prognosis and response to immunotherapy of different subtypes. The purpose of this study was to explore the molecular subtypes and the key genes associated with the prognosis of pancreas cancer patients and study the clinical phenotype, prognosis and response to immunotherapy using single-cell seq data and bulk RNA seq data, and data retrieved from GEO and TCGA databases. Methods: Single-cell seq data and bioinformatics methods were used in this… More >

  • Open Access

    ARTICLE

    Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma

    WENHAO XU1,#, HAOMING LI2,#, YASIR HAMEED3, MOSTAFA A. ABDEL-MAKSOUD4, SAEEDAH MUSAED ALMUTAIRI4, AYMAN MUBARAK4, MOHAMMED AUFY5, WAEL ALTURAIKI6, ABDULAZIZ J. ALSHALANI6, AYMAN M. MAHMOUD7,*, CHEN LI8,*

    Oncology Research, Vol.31, No.5, pp. 819-831, 2023, DOI:10.32604/or.2023.029414

    Abstract N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score… More >

  • Open Access

    ARTICLE

    Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma

    DONGJIE SUN1,2, CHI ZHANG3,*

    Oncology Research, Vol.31, No.5, pp. 753-767, 2023, DOI:10.32604/or.2023.029287

    Abstract Lung adenocarcinoma (LUAD) is the leading cause of cancer-related deaths, accounting for over a million deaths worldwide annually. Immunogenic cell death (ICD) elicits an adaptive immune response. However, the role of ICD-related long noncoding RNAs (lncRNAs) in LUAD is unknown. In this study, we investigated the characteristics of the tumor microenvironment in LUAD, the prognostic significance of ICD-related lncRNAs, and the half-maximal inhibitory concentration (IC50) of possible chemotherapeutic drugs. We sorted prognostic lncRNAs using univariate Cox regression and constructed a risk signature based on them. We then confirmed the model’s accuracy and generated a nomogram.… More > Graphic Abstract

    Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma

  • Open Access

    REVIEW

    Tumor neoantigens: Novel strategies for application of cancer immunotherapy

    HANYANG GUAN1,#, YUE WU2,#, LU LI3,#, YABING YANG1, SHENGHUI QIU1, ZHAN ZHAO1, XIAODONG CHU1, JIASHUAI HE1, ZUYANG CHEN1, YIRAN ZHANG1, HUI DING1, JINGHUA PAN1,*, YUNLONG PAN1,*

    Oncology Research, Vol.31, No.4, pp. 437-448, 2023, DOI:10.32604/or.2023.029924

    Abstract Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen More > Graphic Abstract

    Tumor neoantigens: Novel strategies for application of cancer immunotherapy

  • Open Access

    ARTICLE

    Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing

    WUYAO LIU, CHANGBAO QU, XIAOLU WANG*

    Oncology Research, Vol.31, No.4, pp. 543-567, 2023, DOI:10.32604/or.2023.029563

    Abstract The high immune infiltration and heterogeneity of the microenvironment in clear cell renal cell carcinoma (ccRCC) result in the variability of prognosis and clinical response. While PANoptosis has strong immunogenicity and is worthy of further study. In this study, data from The Cancer Genome Atlas database was used to obtain immune-related PANoptosis lncRNAs with prognostic value. Subsequently, the role of these lncRNAs in cancer immunity, progression and the therapeutic response was analyzed, and a new prediction model was constructed. Additionally, we further explored the biological value of PANoptosis-related lncRNAs using single-cell data from the Gene… More >

  • Open Access

    REVIEW

    Mechanisms and applications of antitumor immunotherapy of responsive drug-loaded nanoparticles in breast cancer

    LETIAN JIN, HETING CHEN, QI RUAN, RUI LIU, YIFENG FAN, XIUFANG XU, DAJIANG WANG*, JIAHUI LU*

    BIOCELL, Vol.47, No.7, pp. 1483-1498, 2023, DOI:10.32604/biocell.2023.028457

    Abstract During the chemotherapy of tumors, the cytotoxic effect of drugs is vital to kill tumor cells, and the delivery of a chemotherapeutic agent is of great importance for optimal therapeutic effects. The high in vivo clearance rate and low delivery efficiency of conventional chemotherapeutic agents affect the therapeutic effect. In recent years, the responsive drug delivery nanosystem has received increasing concern owing to its excellent biocompatibility, stable delivery performance, and controlled drug release strategies. To lucidly explain the cytocidal and immunotherapeutic effects of such responsive nanosystems in breast cancer, this review discusses the various stimuli and More >

  • Open Access

    ARTICLE

    Transcriptome analysis reveals tumor antigen and immune subtypes of melanoma

    JIAHENG XIE1,#, MENGMENG OU1,#, PAN YU1,#, DAN WU2,#, QIKAI TANG3, YUAN CAO4, JING HANG5, LU YIN1, TINGHONG XIANG1, MING WANG1,*, JINGPING SHI1,*

    Oncology Research, Vol.31, No.3, pp. 389-403, 2023, DOI:10.32604/or.2023.029274

    Abstract Purpose: To screen potential tumor antigens for melanoma vaccine development and identify different immune subtypes. Methods: Transcriptional data (HTSEQ-FPKM) and clinical information of a 472 Melanoma cohort GDC TCGA Melanoma (SKCM) were downloaded from the UCSC XENA website (). Subsequently, transcriptome data and clinical information of 210 melanoma cohort GSE65904 were downloaded from Gene Expression Omnibus (GEO), a large global public database. All the transcriptome expression data matrices were log2 transformed for subsequent analysis. GEPIA, TIMER, and IMMPORT databases are also used for analysis. Cell function experiments were performed to validate the role of the… More >

  • Open Access

    REVIEW

    Targeting triple-negative breast cancer: A clinical perspective

    LAZAR S. POPOVIC1,2,*, GORANA MATOVINA-BRKO1, MAJA POPOVIC1,2, KEVIN PUNIE3, ANA CVETANOVIC4,5, MATTEO LAMBERTINI6,7

    Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525

    Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of… More > Graphic Abstract

    Targeting triple-negative breast cancer: A clinical perspective

Displaying 11-20 on page 2 of 37. Per Page